Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for schizophrenia
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Increasing antipsychotic dose for non response in schizophrenia. Many people with schizophrenia do not reach a satisfactory clinical response with a standard dose of an initially prescribed antipsychotic drug. In such cases, clinicians face the dilemma of increasing the antipsychotic dose in order to enhance antipsychotic efficacy.To examine the efficacy of increasing antipsychotic dose compared to keeping the same dose in the treatment of people with schizophrenia who have not responded (...) (as defined in the individual studies) to an initial antipsychotic drug trial. We also examine the adverse effects associated with such a procedure.We searched the Cochrane Schizophrenia Group Trials Register (10 June 2014, 6 October 2015, and 30 March 2017). We examined references of all included studies for further trials.All relevant randomised controlled trials (RCTs), reporting useable data, comparing increasing the antipsychotic dose rather than maintaining the original dose for people
Brexpiprazole (Rexulti) - schizophrenia Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012
Cost-effectiveness of cognitiveâ€“behavioural therapy for sleep disorder added to usual care in patients with schizophrenia: the BEST study Sleep problems are pervasive in people with schizophrenia, but there are no clinical guidelines for their treatment. The Better Sleep Trial (BEST) concluded that suitably adapted cognitive-behavioural therapy (CBT) is likely to be highly effective, although its cost-effectiveness is unknown.To assess the potential cost-effectiveness of CBT for sleep (...) (95% CI -10 529 to 4736) and £1227 (95% CI -10 395 to 5361) lower costs from National Health Service and societal perspectives, respectively. The estimated value of collecting more information about the effects of the CBT on costs and QALYs was approximately £87 million.CBT for insomnia in people with schizophrenia is effective and potentially cost-effective. A larger trial is needed to provide clear evidence about its cost-effectiveness.Patients with schizophrenia have multiple complex health
Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia Discover Portal Discover Portal Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia Published on 14 November 2017 doi: For adults with schizophrenia who continue to have symptoms despite treatment with the antipsychotic drug clozapine, adding amisulpride (another (...) particular drug. Amisulpride is often used in practice, but to date, there had not been much evidence on which to base this decision. Only 68 people with this severe form of schizophrenia were recruited instead of the expected 230, so the ability to detect any clinically significant differences between the groups is reduced. Share your views on the research. Why was this study needed? About 220,000 people in England and Wales have a diagnosis of schizophrenia. In 2007, approximately 30% of the total
Prevalence, factors and reasons associated with missed first appointments among out-patients with schizophrenia at the Federal Neuro-Psychiatric Hospital, Benin City Non-attendance to clinic appointments is associated with poorer treatment outcomes. There is a dearth of information about missed first clinic appointments among patients with schizophrenia in Nigeria.To determine the prevalence, correlates and reasons for missed first appointment among out-patients with schizophrenia (...) at the Federal Neuro-Psychiatric Hospital, Benin City, Nigeria.A cross-sectional descriptive study among 275 out-patients with schizophrenia, using the Mini International Neuro-Psychiatric Interview and the Brief Psychiatric Rating Scale.The prevalence of missed first appointment was 31%. Higher BPRS score was associated with missing the appointment. The main reasons for missed appointments were: forgetting the appointment date and patient's refusal to come to the clinic.Missed first out-patient clinic
Selective noradrenaline reuptake inhibitors for schizophrenia. Schizophrenia is frequently a chronic and disabling illness with a heterogeneous range of symptoms. The positive symptoms usually respond to antipsychotics but the cognitive and negative symptoms of schizophrenia are difficult to treat with conventional antipsychotics and significantly impact on quality of life and social outcomes. Selective noradrenaline reuptake inhibitors (NRIs) increase prefrontal dopamine and noradrenaline (...) levels without significantly affecting subcortical dopamine levels, making them an attractive candidate for treating cognitive and negative symptoms.To investigate the effects of selective noradrenaline reuptake inhibitors (NRIs), compared with a placebo or control treatment, for people with schizophrenia.We searched the Cochrane Schizophrenia Group's Trials Register (up to 7 February 2017) which is based on regular searches of MEDLINE, Embase, CINAHL, BIOSIS, AMED, PubMed, PsycINFO, and registries
Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics The objective of this study was to compare persistence, costs, and healthcare resource utilization in patients with schizophrenia and cardiometabolic comorbidities treated with once-monthly paliperidone palmitate or an oral atypical antipsychotic.Medicaid data from six states (07/2009-03/2015) were used to identify (...) adults with schizophrenia and cardiometabolic comorbidities initiated on once-monthly paliperidone palmitate or an oral atypical antipsychotic (index date) on 01/2010 or after. Persistence to index medication at 12 months (no gap ≥ 90 days) was compared between patients taking once-monthly paliperidone palmitate and an oral atypical antipsychotic using Chi-squared tests. The 12-month post-index healthcare costs and healthcare resource utilization were compared using multivariate ordinary least
Transcranial Magnetic Stimulation for Major Depression and Schizophrenia Transcranial Magnetic Stimulation for Major Depression and Schizophrenia An Evidence Check rapid review brokered by the Sax Institute for the NSW Ministry of Health. August 2017 An Evidence Check rapid review brokered by the Sax Institute for the NSW Ministry of Health. August 2017. This report was prepared by: Ma N, Atukorale Y, Duncan J, Marlow N, Cameron A Research and Evaluation, incorporating ASERNIP-S, Royal (...) www.saxinstitute.org.au email@example.com Phone: +61 2 91889500 Suggested Citation: Ma N, Atukorale Y, Marlow N, Duncan J, Cameron A (2017) Transcranial Magnetic Stimulation for major depression and schizophrenia: an Evidence Check brokered by the Sax Institute (www.saxinstitute.org.au) for the NSW Ministry of Health, 2017. Disclaimer: This Evidence Check Review was produced using the Evidence Check methodology in response to specific questions from the commissioning agency. It is not necessarily
SchizophreniaSchizophrenia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search Schizophrenia Last reviewed: February 2019 Last updated: June 2018 Summary An illness characterised by a co-occurrence of at least two of the following symptoms: hallucinations, delusions, disorganised speech, disorganised/catatonic behaviour, or negative symptoms occurring for a significant period of time during a 1-month period (...) and delusions to frank psychosis. Initially, patients are usually referred by family members. As the illness progresses, patients tend to self-refer or are brought in by a case manager or law enforcement officer. Antipsychotic therapy and psychosocial interventions are effective for most patients, but to varying degrees. Suicidal tendency is one of the most dangerous complications. The lifetime risk of suicide is around 5%. The risk is highest at the onset of the illness. Definition Schizophrenia
N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) G1001C polymorphism and susceptibility to schizophrenia: A meta-analysis. A comprehensive literature search was conducted to identify all case-control studies investigating the association between GRIN1 G1001C polymorphism and schizophrenia susceptibility (MIM: 138249; dbSNP: rs 11146020). A total of 6 eligible studies (including 1639 schizophrenia cases and 1489 controls) were identified for the meta-analysis. Including all studies (...) , there was significant heterogeneity between studies. In overall the GC (OR=1.00, 95 % CI: 0.0.85-1.19) and CC (OR=1.09, 95 % CI: 0.67-1.79) genotypes were not associated with schizophrenia risk compared with the GG genotype. In one study patients were diagnosed using DSM-IIIR criteria and in another study the genotypic frequencies of control subjects showed significant deviation from the expected frequencies according to the Hardy-Weinberg equilibrium. After excluding these studies from the meta-analysis
Zuclopenthixol dihydrochloride for schizophrenia. Oral zuclopenthixol dihydrochloride (Clopixol) is an anti-psychotic treatment for people with psychotic symptoms, especially those with schizophrenia. It is associated with neuroleptic malignant syndrome, a prolongation of the QTc interval, extra-pyramidal reactions, venous thromboembolism and may modify insulin and glucose responses.To determine the effects of zuclopenthixol dihydrochloride for treatment of schizophrenia.We searched (...) the Cochrane Schizophrenia Group's Trials Register (latest search 09 June 2015). There were no language, date, document type, or publication status limitations for inclusion of records in the register.All randomised controlled trials (RCTs) focusing on zuclopenthixol dihydrochloride for schizophrenia. We included trials meeting our inclusion criteria and reporting useable data.We extracted data independently. For binary outcomes, we calculated risk ratio (RR) and its 95% confidence interval (CI
Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses Efficacy of inhaled loxapine 5 or 10 mg in treating agitation was shown using the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) in two Phase III randomised, double-blind, placebo-controlled trials in 344 agitated patients with schizophrenia and 314 patients with bipolar I disorder (Clinicaltrials.gov: NCT00628589, NCT00721955).To examine the five individual items (...) comprising the PANSS-EC and the percentage of patients achieving a clinical response (reduction of ≥40%) in PANSS-EC (Response-40) for these two studies.Response-40 was examined at the primary end-point (2 h) and over time.Response-40 and each PANSS-EC item score were statistically significant v. placebo at 2 h and at each assessment time point for both doses.Inhaled loxapine produced rapid improvement in agitated patients with schizophrenia or bipolar I disorder, achieving Response-40 at the first
Individual differences in schizophrenia Whether there are distinct subtypes of schizophrenia is an important issue to advance understanding and treatment of schizophrenia.To understand and treat individuals with schizophrenia, the aim was to advance understanding of differences between individuals, whether there are discrete subtypes, and how first-episode patients (FEP) may differ from multiple episode patients (MEP).These issues were analysed in 687 FEP and 1880 MEP with schizophrenia using (...) the Positive and Negative Syndrome Scale for (PANSS) schizophrenia before and after antipsychotic medication for 6 weeks.The seven Negative Symptoms were correlated with each other and with P2 (conceptual disorganisation), G13 (disturbance of volition), and G7 (motor retardation). The main difference between individuals was in the cluster of seven negative symptoms, which had a continuous unimodal distribution. Medication decreased the PANSS scores for all the symptoms, which were similar in the FEP
Morphology of the corpus callosum and schizophrenia: A case-control study in Kashan, Iran Corpus Callosum (CC) plays a significant role in hemispheric communication and in lateralized brain function and behaviors. Structural abnormalities in the corpus callosum of schizophrenic patients were reported. However, previous studies regarding the relationship between morphology of CC in patients with schizophrenia and healthy people are controversial.To evaluate the morphological differences (...) of the CC between patients with chronic schizophrenia and healthy people and to examine the relationship between the characteristics of the CC and schizophrenia severity.This cross-sectional study was conducted on 63 patients with chronic schizophrenia (the case group) referred to Kargarnezhad Psychiatric Hospital in Kashan, Iran, and 63 healthy people (the control group) between January 2013 and December 2014. All participants underwent brain magnetic resonance imaging. Shape, anteroposterior length
Different communication strategies for disclosing a diagnosis of schizophrenia and related disorders. Delivering the diagnosis of a serious illness is an important skill in most fields of medicine, including mental health. Research has found that communication skills can impact on a person's recall and understanding of the diagnosis, treatment options and prognosis. People may feel confused and perplexed when information about their illness is not communicated properly. Sharing information (...) diagnoses to people; however, little is known specifically for delivering a diagnosis of schizophrenia.To evaluate evidence from randomised controlled trials (RCTs) for the efficacy of different communication strategies used by clinicians to inform people about the diagnosis and outcome of schizophrenia compared with treatment as usual and to compare efficacy between different communication strategies.On 22 June 2015 and 29 June 2016, we searched the Cochrane Schizophrenia Group's Study-Based Register